Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

SPDR S&P Retail ETF

ProShares UltraPro Dow30

ProShares UltraShort Bloomberg Natrl Gas

Guggenheim Solar ETF

Direxion Technology Bear 3X Shares

Materials Select Sector SPDR

ProShares Trust ProShares Short Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF

Direxion Daily Small Cap Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Technology Bull 3X ETF

ARK Innovation ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Magal Security Systems Ltd.

Direxion Financial Bear 3X Shar

Direxion Daily Semicondct Bull 3X ETF

JELD-WEN Holding Inc. Common Stock

Las Vegas Sands Corp. Common Stock

Century Communities Inc. Common Stock

Kontoor Brands Inc. Common Stock

Bath & Body Works Inc.

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

Leggett & Platt Incorporated Common Stock

Snap Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Civitas Resources Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

AMC Entertainment Holdings Inc. Class A Common Stock

Oklo Inc.

QuantumScape Corporation Class A Common Stock

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Cameco Corporation Common Stock

Twilio Inc. Class A Common Stock

Spotify Technology S.A. Ordinary Shares

Cloudflare Inc. Class A Common Stock

Molina Healthcare Inc Common Stock

Click here to get full coverage on (IDYA) Long Term Investment Analysis - news.stocktradersdaily.com

(IDYA) Long Term Investment Analysis  news.stocktradersdaily.com

(IDYA) Long Term Investment Analysis - news.stocktradersdaily.com

Click here to get full coverage on IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update - PR Newswire

IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update  PR Newswire

IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Awards Major Stock Package Worth $2.1M to Strategic New Hire - Stock Titan

IDEAYA Biosciences Awards Major Stock Package Worth $2.1M to Strategic New Hire  Stock Titan

IDEAYA Biosciences Awards Major Stock Package Worth $2.1M to Strategic New Hire - Stock Titan

Click here to get full coverage on Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849 (NASDAQ:IDYA) - Seeking Alpha

Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849 (NASDAQ:IDYA)  Seeking Alpha

Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849 (NASDAQ:IDYA) - Seeking Alpha

Click here to get full coverage on IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)  PR Newswire

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire

Click here to get full coverage on IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - PR Newswire

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update  PR Newswire

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors - PR Newswire

IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors  PR Newswire

IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma - PR Newswire

IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma  PR Newswire

IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer - PR Newswire

IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer  PR Newswire

IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets - PR Newswire

IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets  PR Newswire

IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer - PR Newswire

IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer  PR Newswire

IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer - PR Newswire

Click here to get full coverage on IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update - PR Newswire

IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update  PR Newswire

IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update - PR Newswire

Click here to get full coverage on IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor - PR Newswire

IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor  PR Newswire

IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor - PR Newswire

Click here to get full coverage on IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024 - PR Newswire

IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024  PR Newswire

IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024 - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors - PR Newswire

IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors  PR Newswire

IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors - PR Newswire

Click here to get full coverage on IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC - PR Newswire

IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC  PR Newswire

IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC - PR Newswire

Click here to get full coverage on IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events - PR Newswire

IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events  PR Newswire

IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma - PR Newswire

IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma  PR Newswire

IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer - PR Newswire

IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer  PR Newswire

IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Expands Oncology Team with 664,600 Share Grant Worth Over $13M - Stock Titan

IDEAYA Biosciences Expands Oncology Team with 664,600 Share Grant Worth Over $13M  Stock Titan

IDEAYA Biosciences Expands Oncology Team with 664,600 Share Grant Worth Over $13M - Stock Titan

Click here to get full coverage on IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen - PR Newswire

IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen  PR Newswire

IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma - PR Newswire

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma  PR Newswire

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma - PR Newswire

Click here to get full coverage on IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events - PR Newswire

IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events  PR Newswire

IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events - PR Newswire

Click here to get full coverage on IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers - PR Newswire

IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers  PR Newswire

IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers - PR Newswire

Click here to get full coverage on Wells Fargo Initiates Coverage on IDEAYA Biosciences (IDYA) with Overweight Rating | IDYA Stock News - GuruFocus

Wells Fargo Initiates Coverage on IDEAYA Biosciences (IDYA) with Overweight Rating | IDYA Stock News  GuruFocus

Wells Fargo Initiates Coverage on IDEAYA Biosciences (IDYA) with Overweight Rating | IDYA Stock News - GuruFocus

Click here to get full coverage on Wells Fargo's Positive Outlook on Ideaya Biosciences (IDYA) | IDYA Stock News - GuruFocus

Wells Fargo's Positive Outlook on Ideaya Biosciences (IDYA) | IDYA Stock News  GuruFocus

Wells Fargo's Positive Outlook on Ideaya Biosciences (IDYA) | IDYA Stock News - GuruFocus

Click here to get full coverage on IDEAYA Leadership to Showcase Ophthalmology and Oncology Progress at Two Elite Conferences - Stock Titan

IDEAYA Leadership to Showcase Ophthalmology and Oncology Progress at Two Elite Conferences  Stock Titan

IDEAYA Leadership to Showcase Ophthalmology and Oncology Progress at Two Elite Conferences - Stock Titan

Click here to get full coverage on IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor - PR Newswire

IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor  PR Newswire

IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor - PR Newswire

Click here to get full coverage on Is IDEAYA Biosciences (NASDAQ:IDYA) In A Good Position To Invest In Growth? - simplywall.st

Is IDEAYA Biosciences (NASDAQ:IDYA) In A Good Position To Invest In Growth?  simplywall.st

Is IDEAYA Biosciences (NASDAQ:IDYA) In A Good Position To Invest In Growth? - simplywall.st

Click here to get full coverage on IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma - PR Newswire

IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma  PR Newswire

IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma - PR Newswire

Click here to get full coverage on IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - PR Newswire

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer  PR Newswire

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - PR Newswire

Click here to get full coverage on Major FDA Breakthrough: IDEAYA's Eye-Saving Cancer Drug Advances to Phase 3 Trial - Stock Titan

Major FDA Breakthrough: IDEAYA's Eye-Saving Cancer Drug Advances to Phase 3 Trial  Stock Titan

Major FDA Breakthrough: IDEAYA's Eye-Saving Cancer Drug Advances to Phase 3 Trial - Stock Titan

Click here to get full coverage on IDEAYA Biosciences CEO Set for Major Healthcare Conference Double-Header: Jefferies and Goldman Sachs - Stock Titan

IDEAYA Biosciences CEO Set for Major Healthcare Conference Double-Header: Jefferies and Goldman Sachs  Stock Titan

IDEAYA Biosciences CEO Set for Major Healthcare Conference Double-Header: Jefferies and Goldman Sachs - Stock Titan

Click here to get full coverage on Why Ideaya Biosciences Is Down Despite Many Positives (NASDAQ:IDYA) - Seeking Alpha

Why Ideaya Biosciences Is Down Despite Many Positives (NASDAQ:IDYA)  Seeking Alpha

Why Ideaya Biosciences Is Down Despite Many Positives (NASDAQ:IDYA) - Seeking Alpha

Click here to get full coverage on IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 2000 Value Index - MarketScreener

IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 2000 Value Index  MarketScreener

IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 2000 Value Index - MarketScreener

Click here to get full coverage on IDEAYA Biosciences: A CFO's Deal-Making Expertise Could Be the Catalyst for a Breakout Year - AInvest

IDEAYA Biosciences: A CFO's Deal-Making Expertise Could Be the Catalyst for a Breakout Year  AInvest

IDEAYA Biosciences: A CFO's Deal-Making Expertise Could Be the Catalyst for a Breakout Year - AInvest

Click here to get full coverage on Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later - Seeking Alpha

Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later  Seeking Alpha

Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later - Seeking Alpha

Click here to get full coverage on Why IDEAYA's Russell Exit Could Be a Biotech Contrarian's Dream - AInvest

Why IDEAYA's Russell Exit Could Be a Biotech Contrarian's Dream  AInvest

Why IDEAYA's Russell Exit Could Be a Biotech Contrarian's Dream - AInvest

Click here to get full coverage on IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024 - PR Newswire

IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024  PR Newswire

IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024 - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors - PR Newswire

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors  PR Newswire

IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors - PR Newswire

Click here to get full coverage on Why IDEAYA Biosciences, Inc. (IDYA) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential - Insider Monkey

Why IDEAYA Biosciences, Inc. (IDYA) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential  Insider Monkey

Why IDEAYA Biosciences, Inc. (IDYA) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential - Insider Monkey

Click here to get full coverage on IDEAYA Secures FDA Breakthrough Status as 300+ Patient Melanoma Trial Advances Toward Key 2025 Readout - Stock Titan

IDEAYA Secures FDA Breakthrough Status as 300+ Patient Melanoma Trial Advances Toward Key 2025 Readout  Stock Titan

IDEAYA Secures FDA Breakthrough Status as 300+ Patient Melanoma Trial Advances Toward Key 2025 Readout - Stock Titan

Click here to get full coverage on IDEAYA Biosciences Appoints New Chief Financial Officer - TipRanks

IDEAYA Biosciences Appoints New Chief Financial Officer  TipRanks

IDEAYA Biosciences Appoints New Chief Financial Officer - TipRanks

Click here to get full coverage on IDEAYA Biosciences Holds Annual Stockholders Meeting - TipRanks

IDEAYA Biosciences Holds Annual Stockholders Meeting  TipRanks

IDEAYA Biosciences Holds Annual Stockholders Meeting - TipRanks

Click here to get full coverage on Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming - Seeking Alpha

Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming  Seeking Alpha

Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming - Seeking Alpha

Click here to get full coverage on Top 11 Small Cap Stocks to Buy with Biggest Upside Potential - Insider Monkey

Top 11 Small Cap Stocks to Buy with Biggest Upside Potential  Insider Monkey

Top 11 Small Cap Stocks to Buy with Biggest Upside Potential - Insider Monkey

Click here to get full coverage on Breakthrough Cancer Drug IDE849 Gets FDA Green Light: Early Data Shows Promise in Multiple Tumors - Stock Titan

Breakthrough Cancer Drug IDE849 Gets FDA Green Light: Early Data Shows Promise in Multiple Tumors  Stock Titan

Breakthrough Cancer Drug IDE849 Gets FDA Green Light: Early Data Shows Promise in Multiple Tumors - Stock Titan

Click here to get full coverage on IDEAYA Announces Pricing of Public Offering - PR Newswire

IDEAYA Announces Pricing of Public Offering  PR Newswire

IDEAYA Announces Pricing of Public Offering - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Kilgore News Herald

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)  Kilgore News Herald

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Kilgore News Herald

Click here to get full coverage on IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Victoria Advocate

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)  The Victoria Advocate

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Victoria Advocate

Click here to get full coverage on Ideaya Biosciences initiated with an Overweight at Wells Fargo - TipRanks

Ideaya Biosciences initiated with an Overweight at Wells Fargo  TipRanks

Ideaya Biosciences initiated with an Overweight at Wells Fargo - TipRanks

Click here to get full coverage on IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer - PR Newswire

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer  PR Newswire

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer - PR Newswire

Click here to get full coverage on IDEAYA Biosciences Advances Synthetic Lethality With IDE397 Success - Seeking Alpha

IDEAYA Biosciences Advances Synthetic Lethality With IDE397 Success  Seeking Alpha

IDEAYA Biosciences Advances Synthetic Lethality With IDE397 Success - Seeking Alpha

Click here to get full coverage on IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events - BioSpace

IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events  BioSpace

IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events - BioSpace

Click here to get full coverage on IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events – Company Announcement - Financial Times

IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events – Company Announcement  Financial Times

Ideaya Biosciences Inc (IDYA)

Price Chart

Key Statistics

Technicals

About IDYA

Latest News

(IDYA) Long Term Investment Analysis - news.stocktradersdaily.com

IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update - PR Newswire

IDEAYA Biosciences Awards Major Stock Package Worth $2.1M to Strategic New Hire - Stock Titan

Advanced Charts

Top Gainers

Top Losers